Cargando…

Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial

BACKGROUND: Dairy products are a major contributor to dietary SFA. Partial replacement of milk SFA with unsaturated fatty acids (FAs) is possible through oleic-acid rich supplementation of the dairy cow diet. To assess adherence to the intervention of SFA-reduced, MUFA-enriched dairy product consump...

Descripción completa

Detalles Bibliográficos
Autores principales: Markey, Oonagh, Vasilopoulou, Dafni, Kliem, Kirsty E., Koulman, Albert, Fagan, Colette C., Summerhill, Keith, Wang, Laura Y., Grandison, Alistair S., Humphries, David J., Todd, Susan, Jackson, Kim G., Givens, David I., Lovegrove, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442645/
https://www.ncbi.nlm.nih.gov/pubmed/28535777
http://dx.doi.org/10.1186/s12937-017-0249-2
_version_ 1783238434364588032
author Markey, Oonagh
Vasilopoulou, Dafni
Kliem, Kirsty E.
Koulman, Albert
Fagan, Colette C.
Summerhill, Keith
Wang, Laura Y.
Grandison, Alistair S.
Humphries, David J.
Todd, Susan
Jackson, Kim G.
Givens, David I.
Lovegrove, Julie A.
author_facet Markey, Oonagh
Vasilopoulou, Dafni
Kliem, Kirsty E.
Koulman, Albert
Fagan, Colette C.
Summerhill, Keith
Wang, Laura Y.
Grandison, Alistair S.
Humphries, David J.
Todd, Susan
Jackson, Kim G.
Givens, David I.
Lovegrove, Julie A.
author_sort Markey, Oonagh
collection PubMed
description BACKGROUND: Dairy products are a major contributor to dietary SFA. Partial replacement of milk SFA with unsaturated fatty acids (FAs) is possible through oleic-acid rich supplementation of the dairy cow diet. To assess adherence to the intervention of SFA-reduced, MUFA-enriched dairy product consumption in the RESET (REplacement of SaturatEd fat in dairy on Total cholesterol) study using 4-d weighed dietary records, in addition to plasma phospholipid FA (PL-FA) status. METHODS: In a randomised, controlled, crossover design, free-living UK participants identified as moderate risk for CVD (n = 54) were required to replace habitually consumed dairy foods (milk, cheese and butter), with study products with a FA profile typical of retail products (control) or SFA-reduced, MUFA-enriched profile (modified), for two 12-week periods, separated by an 8-week washout period. A flexible food-exchange model was used to implement each isoenergetic high-fat, high-dairy diet (38% of total energy intake (%TE) total fat): control (dietary target: 19%TE SFA; 11%TE MUFA) and modified (16%TE SFA; 14%TE MUFA). RESULTS: Following the modified diet, there was a smaller increase in SFA (17.2%TE vs. 19.1%TE; p < 0.001) and greater increase in MUFA intake (15.4%TE vs. 11.8%TE; p < 0.0001) when compared with the control. PL-FA analysis revealed lower total SFAs (p = 0.006), higher total cis-MUFAs and trans-MUFAs (both p < 0.0001) following the modified diet. CONCLUSION: The food-exchange model was successfully used to achieve RESET dietary targets by partial replacement of SFAs with MUFAs in dairy products, a finding reflected in the PL-FA profile and indicative of objective dietary compliance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02089035, date 05-01-2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12937-017-0249-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5442645
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54426452017-05-25 Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial Markey, Oonagh Vasilopoulou, Dafni Kliem, Kirsty E. Koulman, Albert Fagan, Colette C. Summerhill, Keith Wang, Laura Y. Grandison, Alistair S. Humphries, David J. Todd, Susan Jackson, Kim G. Givens, David I. Lovegrove, Julie A. Nutr J Research BACKGROUND: Dairy products are a major contributor to dietary SFA. Partial replacement of milk SFA with unsaturated fatty acids (FAs) is possible through oleic-acid rich supplementation of the dairy cow diet. To assess adherence to the intervention of SFA-reduced, MUFA-enriched dairy product consumption in the RESET (REplacement of SaturatEd fat in dairy on Total cholesterol) study using 4-d weighed dietary records, in addition to plasma phospholipid FA (PL-FA) status. METHODS: In a randomised, controlled, crossover design, free-living UK participants identified as moderate risk for CVD (n = 54) were required to replace habitually consumed dairy foods (milk, cheese and butter), with study products with a FA profile typical of retail products (control) or SFA-reduced, MUFA-enriched profile (modified), for two 12-week periods, separated by an 8-week washout period. A flexible food-exchange model was used to implement each isoenergetic high-fat, high-dairy diet (38% of total energy intake (%TE) total fat): control (dietary target: 19%TE SFA; 11%TE MUFA) and modified (16%TE SFA; 14%TE MUFA). RESULTS: Following the modified diet, there was a smaller increase in SFA (17.2%TE vs. 19.1%TE; p < 0.001) and greater increase in MUFA intake (15.4%TE vs. 11.8%TE; p < 0.0001) when compared with the control. PL-FA analysis revealed lower total SFAs (p = 0.006), higher total cis-MUFAs and trans-MUFAs (both p < 0.0001) following the modified diet. CONCLUSION: The food-exchange model was successfully used to achieve RESET dietary targets by partial replacement of SFAs with MUFAs in dairy products, a finding reflected in the PL-FA profile and indicative of objective dietary compliance. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02089035, date 05-01-2014. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12937-017-0249-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-23 /pmc/articles/PMC5442645/ /pubmed/28535777 http://dx.doi.org/10.1186/s12937-017-0249-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Markey, Oonagh
Vasilopoulou, Dafni
Kliem, Kirsty E.
Koulman, Albert
Fagan, Colette C.
Summerhill, Keith
Wang, Laura Y.
Grandison, Alistair S.
Humphries, David J.
Todd, Susan
Jackson, Kim G.
Givens, David I.
Lovegrove, Julie A.
Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial
title Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial
title_full Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial
title_fullStr Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial
title_full_unstemmed Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial
title_short Plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial
title_sort plasma phospholipid fatty acid profile confirms compliance to a novel saturated fat-reduced, monounsaturated fat-enriched dairy product intervention in adults at moderate cardiovascular risk: a randomized controlled trial
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442645/
https://www.ncbi.nlm.nih.gov/pubmed/28535777
http://dx.doi.org/10.1186/s12937-017-0249-2
work_keys_str_mv AT markeyoonagh plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT vasilopouloudafni plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT kliemkirstye plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT koulmanalbert plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT fagancolettec plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT summerhillkeith plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT wanglauray plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT grandisonalistairs plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT humphriesdavidj plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT toddsusan plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT jacksonkimg plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT givensdavidi plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial
AT lovegrovejuliea plasmaphospholipidfattyacidprofileconfirmscompliancetoanovelsaturatedfatreducedmonounsaturatedfatenricheddairyproductinterventioninadultsatmoderatecardiovascularriskarandomizedcontrolledtrial